These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7598637)

  • 1. Premenstrual dysphoric disorder and response to cholecystokinin-tetrapeptide.
    Le Melledo JM; Bradwejn J; Koszycki D; Bichet D
    Arch Gen Psychiatry; 1995 Jul; 52(7):605-6. PubMed ID: 7598637
    [No Abstract]   [Full Text] [Related]  

  • 2. Premenstrual dysphoric disorders, anxiety, and depressions: vulnerability traits or comorbidity.
    Halbreich U
    Arch Gen Psychiatry; 1995 Jul; 52(7):606. PubMed ID: 7598638
    [No Abstract]   [Full Text] [Related]  

  • 3. Arginine-vasopressin and oxytocin response to cholecystokinin-tetrapeptide.
    Le Mellédo JM; Bradwejn J; Koszycki D; Bellavance F; Bichet D
    Peptides; 2001 Aug; 22(8):1349-57. PubMed ID: 11457531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings.
    Bradwejn J; Koszycki D; Payeur R; Bourin M; Borthwick H
    Am J Psychiatry; 1992 Jul; 149(7):962-4. PubMed ID: 1609879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of aging on cholecystokinin-induced panic.
    Flint AJ; Koszycki D; Vaccarino FJ; Cadieux A; Boulenger JP; Bradwejn J
    Am J Psychiatry; 1998 Feb; 155(2):283-5. PubMed ID: 9464213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder (PMDD) during their follicular and luteal phases.
    Le Mellédo JM; Merani S; Koszycki D; Bellavance F; Palmour R; Gutkowska J; Steinberg S; Bichet DG; Bradwejn J
    Neuropsychopharmacology; 1999 Jan; 20(1):81-91. PubMed ID: 9885787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers.
    Bradwejn J; LeGrand JM; Koszycki D; Bates JH; Bourin M
    Am J Psychiatry; 1998 Feb; 155(2):280-2. PubMed ID: 9464212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Provocation of a posttraumatic flashback by cholecystokinin tetrapeptide?
    Kellner M; Levengood R; Yehuda R; Wiedemann K
    Am J Psychiatry; 1998 Sep; 155(9):1299. PubMed ID: 9734561
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to flumazenil in women with premenstrual dysphoric disorder.
    Le Mellédo JM; Van Driel M; Coupland NJ; Lott P; Jhangri GS
    Am J Psychiatry; 2000 May; 157(5):821-3. PubMed ID: 10784479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the beta-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms.
    Le Mellédo JM; Bradwejn J; Koszycki D; Bichet DG; Bellavance F
    Biol Psychiatry; 1998 Sep; 44(5):364-6. PubMed ID: 9755359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers.
    Koszycki D; Cox BJ; Bradwejn J
    Am J Psychiatry; 1993 Dec; 150(12):1881-3. PubMed ID: 8238648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.
    Bradwejn J; Koszycki D; Couëtoux du Tertre A; van Megen H; den Boer J; Westenberg H
    Arch Gen Psychiatry; 1994 Jun; 51(6):486-93. PubMed ID: 8192551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specificity of panic response to CO(2) inhalation in panic disorder: a comparison with major depression and premenstrual dysphoric disorder.
    Kent JM; Papp LA; Martinez JM; Browne ST; Coplan JD; Klein DF; Gorman JM
    Am J Psychiatry; 2001 Jan; 158(1):58-67. PubMed ID: 11136634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder.
    Ströhle A; Kellner M; Holsboer F; Wiedemann K
    Am J Psychiatry; 2001 Sep; 158(9):1514-6. PubMed ID: 11532742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings.
    Wiedemann K; Jahn H; Yassouridis A; Kellner M
    Arch Gen Psychiatry; 2001 Apr; 58(4):371-7. PubMed ID: 11296098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients.
    Bradwejn J; Koszycki D
    Am J Psychiatry; 1994 Feb; 151(2):261-3. PubMed ID: 8296900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of the menstrual cycle on reactivity to a CO
    Nillni YI; Pineles SL; Rohan KJ; Zvolensky MJ; Rasmusson AM
    Cogn Behav Ther; 2017 Apr; 46(3):239-249. PubMed ID: 27687294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.
    Bradwejn J; Koszycki D; Shriqui C
    Arch Gen Psychiatry; 1991 Jul; 48(7):603-10. PubMed ID: 2069490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anxiety sensitivity and cholecystokinin tetrapeptide challenge.
    McNally RJ
    Am J Psychiatry; 1995 Feb; 152(2):300-1. PubMed ID: 7840376
    [No Abstract]   [Full Text] [Related]  

  • 20. Cholecystokinin tetrapeptide-induced calcium mobilization in T cells of patients with panic disorder, major depression, or schizophrenia.
    Akiyoshi J; Isogawa K; Tsutsumi T; Kasturagi S; Kohno K; Furuta M; Yamamoto Y; Yamada K; Fujii I
    Biol Psychiatry; 1997 Jul; 42(2):151-4. PubMed ID: 9209734
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.